Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | FES | P07332 | 1/20 | 0.45 |
| ▸ | FER | P16591 | 1/20 | 0.45 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.45 |
| ▸ | TEC | P42680 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18018888 | 0.91 | ALK (0.49) | EGFRPTK2ALKFESFER | |
| SCHEMBL18018861 | 0.89 | TTK (0.48) | EGFRPTK2ALKFESJAK3 | |
| SCHEMBL18018890 | 0.89 | JAK3 (0.45) | EGFRPTK2ALKGAKFES | |
| SCHEMBL22985882 | 0.87 | EGFR (0.48) | EGFRPTK2ALKGAKFES | |
| SCHEMBL18018913 | 0.86 | EGFR (0.51) | EGFRPTK2ALKFESTTK | |
| SCHEMBL18018892 | 0.85 | TTK (0.50) | EGFRPTK2ALKFESFER | |
| SCHEMBL18018863 | 0.85 | ALK (0.49) | EGFRALKFESJAK3BTK | |
| SCHEMBL18018904 | 0.83 | LRRK2 (0.51) | EGFRALKFESTTK | |
| SCHEMBL18018868 | 0.82 | EGFR (0.47) | EGFRPTK2ALKFESFER | |
| SCHEMBL18018866 | 0.81 | EGFR (0.49) | EGFRALKFESTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2016130920-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | LRRK2, PARK7, PINK1 | EGFR 2819/4885PTK2 574/4885ALK 4666/4885 |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | LRRK2, PARK7, PINK1 | EGFR 2819/4885PTK2 574/4885ALK 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.